Clinical Edge Journal Scan

Web-based mindfulness program improves depressive symptoms in MS


 

Key clinical point: Patients with multiple sclerosis (pwMS) who participated in a web-based mindfulness-based intervention (MBI) showed significant improvements in depressive symptoms and health-related quality of life (HRQoL).

Major finding: The MBI group showed a significant improvement in depressive symptoms compared with the waitlist (Cohen’s d 0.39; 95% CI, 0.034-0.742), with patients with recurrent depressive symptoms benefitting the most ( P = .034). MBI had a positive effect on HRQoL regardless of previous depressive history ( P = .009).

Study details: The findings come from a randomized controlled trial involving 132 pwMS with or without a history of recurrent depression, and who received either an internet-delivered MBI (n = 69) or were assigned to a waitlist (n = 63).

Disclosures: This study was supported by the National Health and Medical Research Council and Multiple Sclerosis Research, Australia. The authors declared no conflict of interests.

Source: Sesel AL et al. Mult Scler. 2022 (Feb 7). Doi: 10.1177/13524585211068002.

Recommended Reading

Clinical Edge Journal Scan Commentary: Multiple Sclerosis February 2022
ICYMI Multiple Sclerosis
Third COVID-19 vaccine dose shows benefit in MS patients with a weak response after 2 doses
ICYMI Multiple Sclerosis
Multiple sclerosis relapses are prevalent after natalizumab cessation during pregnancy
ICYMI Multiple Sclerosis
Multiple sclerosis: Evidence spanning 3 decades finds no influence of DMTs on neoplasm incidence
ICYMI Multiple Sclerosis
Differential impact of multiple sclerosis therapies on SARS-CoV-2 vaccine-induced immune response
ICYMI Multiple Sclerosis
Multiple sclerosis: Excellent response to SARS-CoV-2 vaccine in patients with MS
ICYMI Multiple Sclerosis
High or increasing sNfl level predictive of impending relapses in active multiple sclerosis
ICYMI Multiple Sclerosis
sNfL and disease course in progressive MS without acute inflammation: Is there a link?
ICYMI Multiple Sclerosis
Primary progressive MS: No difference in efficacy between rituximab and ocrelizumab in real world
ICYMI Multiple Sclerosis
Early decline in lymphocyte count best predicts DMF-associated lymphopenia in relapsing MS
ICYMI Multiple Sclerosis